These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26387622)

  • 1. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles.
    Kunda NK; Alfagih IM; Miyaji EN; Figueiredo DB; Gonçalves VM; Ferreira DM; Dennison SR; Somavarapu S; Hutcheon GA; Saleem IY
    Int J Pharm; 2015 Nov; 495(2):903-12. PubMed ID: 26387622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation.
    Kunda NK; Alfagih IM; Dennison SR; Tawfeek HM; Somavarapu S; Hutcheon GA; Saleem IY
    Pharm Res; 2015 Apr; 32(4):1341-53. PubMed ID: 25297713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder pulmonary delivery of cationic PGA-co-PDL nanoparticles with surface adsorbed model protein.
    Kunda NK; Alfagih IM; Dennison SR; Somavarapu S; Merchant Z; Hutcheon GA; Saleem IY
    Int J Pharm; 2015 Aug; 492(1-2):213-22. PubMed ID: 26169146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.
    Haughney SL; Petersen LK; Schoofs AD; Ramer-Tait AE; King JD; Briles DE; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2013 Sep; 9(9):8262-71. PubMed ID: 23774257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein A.
    Anish C; Upadhyay AK; Sehgal D; Panda AK
    Int J Pharm; 2014 May; 466(1-2):198-210. PubMed ID: 24631054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung.
    Sham JO; Zhang Y; Finlay WH; Roa WH; Löbenberg R
    Int J Pharm; 2004 Jan; 269(2):457-67. PubMed ID: 14706257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System.
    Yuki Y; Uchida Y; Sawada SI; Nakahashi-Ouchida R; Sugiura K; Mori H; Yamanoue T; Machita T; Honma A; Kurokawa S; Mukerji R; Briles DE; Akiyoshi K; Kiyono H
    Mol Pharm; 2021 Apr; 18(4):1582-1592. PubMed ID: 33621107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.
    Muttil P; Pulliam B; Garcia-Contreras L; Fallon JK; Wang C; Hickey AJ; Edwards DA
    AAPS J; 2010 Dec; 12(4):699-707. PubMed ID: 20878294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs.
    Figueiredo DB; Kaneko K; Rodrigues TDC; MacLoughlin R; Miyaji EN; Saleem I; Gonçalves VM
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of particle formulation on dry powder inhalation efficiency.
    Hassan MS; Lau R
    Curr Pharm Des; 2010 Jul; 16(21):2377-87. PubMed ID: 20618158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an inhalable, stimuli-responsive particulate system for delivery to deep lung tissue.
    Abbas Y; Azzazy HM; Tammam S; Lamprecht A; Ali ME; Schmidt A; Sollazzo S; Mathur S
    Colloids Surf B Biointerfaces; 2016 Oct; 146():19-30. PubMed ID: 27244047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
    Wu X; Hayes D; Zwischenberger JB; Kuhn RJ; Mansour HM
    Drug Des Devel Ther; 2013; 7():59-72. PubMed ID: 23403805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery.
    Sinsuebpol C; Chatchawalsaisin J; Kulvanich P
    Drug Des Devel Ther; 2013; 7():861-73. PubMed ID: 24039397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation.
    Amaro MI; Tewes F; Gobbo O; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
    Int J Pharm; 2015 Apr; 483(1-2):6-18. PubMed ID: 25660067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.
    Rodrigues TC; Oliveira MLS; Soares-Schanoski A; Chavez-Rico SL; Figueiredo DB; Gonçalves VM; Ferreira DM; Kunda NK; Saleem IY; Miyaji EN
    PLoS One; 2018; 13(1):e0191692. PubMed ID: 29360883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.